MacroGenics, Inc. (MGNX) Financials
MGNX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 298.4 million | 145.8 million |
2023-09-30 | 340.0 million | 146.0 million |
2023-06-30 | 305.7 million | 134.1 million |
2023-03-31 | 343.5 million | 234.2 million |
MGNX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -28.7 million | 4.4 million |
2023-09-30 | -35.7 million | 4.8 million |
2023-06-30 | -2.4 million | 4.4 million |
2023-03-31 | -13.2 million | 4.8 million |
MGNX Net Income
No data available :(
MGNX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 229.8 million | - | 34.0 million |
2023-09-30 | 256.4 million | - | 34.1 million |
2023-06-30 | 240.3 million | - | 34.3 million |
2023-03-31 | 241.7 million | - | 34.5 million |
MGNX Shares Outstanding
MGNX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 620000 | 47.4 million | 12.6 million | - |
2023-09-30 | 499000 | 30.1 million | 12.4 million | - |
2023-06-30 | 286000 | 43.2 million | 13.7 million | - |
2023-03-31 | 359000 | 45.9 million | 13.5 million | - |
MGNX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 11.0 million | -4.2 million |
2023-09-30 | 10.4 million | 85000 |
2023-06-30 | 13.1 million | 1.2 million |
2023-03-31 | 24.2 million | 3.5 million |
MGNX
Price: $14.56
52 week price:
Payout Ratio Range:
Earnings Per Share: -0.15 USD
P/E Ratio: 21.30
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 382181
Ebitda: -45.8 millionMarket Capitalization: 1.1 billion